Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 258 Carcinoma, Non-Small-Cell Lung 226 Carcinoma, Renal Cell 142 Neoplasm Metastasis 97 Neoplasms 92 Squamous Cell Carcinoma of Head and Neck 84 Carcinoma, Hepatocellular 84 Colorectal Neoplasms 80 Lung Neoplasms 73 Stomach Neoplasms 56 Pancreatic Neoplasms 56 Carcinoma, Transitional Cell 49 Hodgkin Disease 47 Urinary Bladder Neoplasms 42 Breast Neoplasms 40 Ovarian Neoplasms 37 Head and Neck Neoplasms 37 Triple Negative Breast Neoplasms 34 Small Cell Lung Carcinoma 33 Sarcoma 32 Glioblastoma 32 Brain Neoplasms 32 Prostatic Neoplasms 31 Recurrence 27 Kidney Neoplasms 27 Multiple Myeloma 25 Uveal Melanoma 23 Esophageal Neoplasms 23 Uterine Cervical Neoplasms 22 Skin Neoplasms 22

Interventions

pembrolizumab 2 atezolizumab 2 trastuzumab deruxtecan 1 toripalimab 1 pertuzumab 1 fludarabine 1 durvalumab 1 cabazitaxel 1 XRP6258 1 Trastuzumab 1 S-Adenosylmethionine 1 Ramucirumab 1 Paclitaxel 1 Oxaliplatin 1 Nivolumab 1 Leucovorin 1 Irinotecan 1 Fluorouracil 1 Etoposide 1 Cyclophosphamide 1 Cetuximab 1 Carboplatin 1 Capecitabine 1 Bevacizumab 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Solid Cancer × Nivolumab × Clear all

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡